KemPharm Inc

KMPH | $5.46 6.04% 0

(0.0% 1d) (0.7% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea treatment profitable

add to watch list Paper trade email alert is off

Bionik Laboratories Corp

BNKL | $0.1 -39.39% 1.8K

Manufacturing

(0.0% 1d) (0.0% 1m) (-79.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-87.07% volume)
Earnings Calendar:
Market Cap: $ 1,248,043

Sec Filling | Patents | 19 employees

bionik laboratories (otcqx: bnkl) is a pioneering medical device and robotics company developing transformational robotic rehabilitation technologies for individuals with neurological disorders. the company is dedicated to provide individuals with restricted mobility an improvement in overall health, comfort, accessibility, and quality of life through the commercialization of its proprietary products. the company’s lead program, arke™ is the most comprehensive lower-body exoskeleton that allows paraplegics and as well as other wheelchair users the ability to rehabilitate through walking and other motion. currently in clinical development, arke will initially be used in a rehabilitation environment, with the goal of being made available for home use.

add to watch list Paper trade email alert is off

Greenbrook TMS Inc

GBNH | $0.121 -4.88% 6M

Manufacturing

(0.0% 1d) (0.0% 1m) (-76.8% 1y) (-24.5% 2d) (-24.5% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 4,936,822
https://greenbrooktms.com
Sec Filling | Patents | n/a employees

Operating through 123 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared,non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 370,000 TMS treatments to close to 10,000 patients struggling with depression.

treatment

add to watch list Paper trade email alert is off

ATAI Life Sciences N.V.

ATAI | $1.85 -3.14% -3.24% 940K

Manufacturing

(0.0% 1d) (10.8% 1m) (-14.7% 1y) (0.0% 2d) (-14.2% 3d) (-10.6% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 307,148,833
https://www.atai.life
Sec Filling | Patents | 35 employees

(DE) atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.

treatment profitable msa

add to watch list Paper trade email alert is off

Femasys Inc

FEMY | $1.33 1.53% 1.5% 160K

Manufacturing

(0.0% 1d) (-23.3% 1m) (47.2% 1y) (3.1% 2d) (1.5% 3d) (-1.5% 7d) (Infinity% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 29,392,132

Sec Filling | Patents | 35 employees

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

contraception

add to watch list Paper trade email alert is off

GH Research PLC

GHRS | $11.055 -1.21% -1.22% 63K

Manufacturing

(0.0% 1d) (4.2% 1m) (38.7% 1y) (0.0% 2d) (0.4% 3d) (-5.9% 7d) (-18.34% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 575,171,143
https://www.ghres.com
Sec Filling | Patents | 2021 employees

(IE) GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

treatment

add to watch list Paper trade email alert is off

Nuwellis Inc

NUWE | $0.255 -2.07% -2.12% 230K

Manufacturing

(0.0% 1d) (-39.8% 1m) (-93.9% 1y) (0.0% 2d) (-7.1% 3d) (-29.4% 7d) (-72.56% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,734,368
https://www.nuwellis.com
Sec Filling | Patents | 15027 employees

(US) Nuwellis, Inc. , formally CHF Solutions, is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions

brands

add to watch list Paper trade email alert is off

ReShape Lifesciences Inc.

RSLS | $0.1707 3.93% 77K

Manufacturing

(0.0% 1d) (-4.5% 1m) (-93.8% 1y) (0.0% 2d) (6.3% 3d) (3.3% 7d) (-70.83% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,004,125
https://www.obalon.com
Sec Filling | Patents | 2 employees

(United States) Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

add to watch list Paper trade email alert is off

Wrap Technologies Inc

WRAP | News | $2.01 -3.37% -3.48% 180K

Manufacturing

(0.0% 1d) (-24.2% 1m) (49.3% 1y) (0.0% 2d) (4.7% 3d) (4.2% 7d) (-42.32% volume)
Earnings Calendar: 2024-04-30
Market Cap: $ 88,870,480
https://wrap.com
Sec Filling | Patents | 52 employees

Wrap Technologies is an innovator of modern policing solutions. The Company's BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company's Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge.

add to watch list Paper trade email alert is off